ReviewJournal of pain research2017
Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.
Review in Journal of pain research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07451769 (Selective Activation of the Adrenomedullin Receptors in Migraine), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Selective Activation of the Adrenomedullin Receptors in Migraine: A Randomized, Double-Blind, Placebo-Controlled Crossover Study
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review.European journal of medical research · 2022Pooled it
- Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study.Neurology and therapy · 2024Article
- Update on GPCR-based targets for the development of novel antidepressants.Molecular psychiatry · 2022Review
- Migraine patients in Germany - need for medical recognition and new preventive treatments: results from the PANORAMA survey.The journal of headache and pain · 2021Article
- Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence-What Do We Know So Far?Pharmaceuticals (Basel, Switzerland) · 2021Review
- CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine.Journal of clinical medicine · 2021Review
- A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB.The journal of headache and pain · 2020Article
- Dawn of a New RAMPage.Trends in pharmacological sciences · 2020Review
- Co-occurrence of pain syndromes.Journal of neural transmission (Vienna, Austria : 1996) · 2020Review
- Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study.Frontiers in neurology · 2020Article
- Acute headache management in emergency department. A narrative review.Internal and emergency medicine · 2020Review
- Therapeutic novelties in migraine: new drugs, new hope?The journal of headache and pain · 2019Review
- CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review.Current pain and headache reports · 2019Review
- New Trends in Migraine Pharmacology: Targeting Calcitonin Gene-Related Peptide (CGRP) With Monoclonal Antibodies.Frontiers in pharmacology · 2019Review
- The Efficacy of Shinbaro for the Preventive Treatment of Migraine: A Pilot Study.Evidence-based complementary and alternative medicine : eCAM · 2019Article
- Effects of topical vs injection treatment of cervical myofascial trigger points on headache symptoms in migraine patients: a retrospective analysis.The journal of headache and pain · 2018Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine is a highly disabling neurological condition, and preventative treatment still remains problematic, due to aspecificity of the majority of the currently available prophylactic drugs. Calcitonin-gene-related peptide (CGRP) plays a crucial role in migraine pathophysiology; agents aimed at blocking its activity have, therefore, been developed in recent years, among which are monoclonal antibodies (mAbs) against CGRP, to prevent migraine. Erenumab is the only mAb that targets the CGRP receptor instead of the ligand, with high specificity and affinity of binding. This review will report on the most recent data on erenumab characteristics and on the results of clinical trials on its employment in the prevention of episodic migraine (4-14 monthly migraine days): one Phase II and two Phase III trials (completed) and one Phase III trial (ongoing). Monthly subcutaneous administration (70 mg or 140 mg) of erenumab vs placebo for 3-6 months showed significantly higher efficacy in reducing the mean monthly number of migraine days and the use of migraine-specific medication, and in decreasing physical impairment and impact of migraine on everyday activities (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.